Do you want to read an article? Please log in or register.
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
Multiple Sclerosis
Related content
SPECIAL REPORT
Multiple Sclerosis
Vaccination Readiness in Multiple Sclerosis
Multiple Sclerosis
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study
Mult Scler.
Chitnis T, Banwell B, Krupp L, Arnold DL, Bar-Or A, Brück W, Giovannoni G, Greenberg B, Ghezzi A, Waubant E, Rostasy K, Deiva K, Huppke P, Wolinsky JS, Zhang Y, Azmon A, K-Laflamme A, Karan R, Gärtner J
doi: 10.1177/1352458520936934.
Multiple Sclerosis
The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study
PLoS One.
Izquierdo G, Damas F, Páramo MD, Ruiz-Peña JL, Navarro G
doi: 10.1371/
Multiple Sclerosis
Real Life Long-Term Effectiveness of Fingolimod in Swiss Patients with Relapsing-Remitting Multiple Sclerosis (REALITE)
doi: 10.1111/ene.13594.
EpilepsyMultiple Sclerosis
De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine
Mult Scler.
Panicucci E, Cohen M, Bourg V, Rocher F, Thomas P, Lebrun C
doi: 10.1177/1352458518790379.
Multiple Sclerosis
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies
Mult Scler
De Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist T, Coyle PK, Dangond F, Keller B, Alexandri N, Galazka A
doi: 10.1177/13524585211010294
Multiple Sclerosis
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
Mult Scler Relat Disord.
Novi G, Mikulska M, Briano F, Toscanini F, Tazza F, Uccelli A, Inglese M
doi: 10.1016/j.msard.2020.102120.
SPECIAL REPORT
Multiple Sclerosis
Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis
RECOMMENDED
Stroke
Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Stroke.
Ntaios G, Michel P, Georgiopoulos G, Guo Y, Li W, Xiong J, Calleja P, Ostos F, González-Ortega G, Fuentes B, Alonso de Leciñana M, Díez-Tejedor E, García-Madrona S, Masjuan J, DeFelipe A, Turc G, Gonçalves B, Domigo V, Dan GA, Vezeteu R, Christensen H, Christensen LM, Meden P, Hajdarevic L, Rodriguez-Lopez A, Díaz-Otero F, García-Pastor A, Gil-Nuñez A, Maslias E, Strambo D, Werring DJ, Chandratheva A, Benjamin L, Simister R, Perry R, Beyrouti R, Jabbour P, Sweid A, Tjoumakaris S, Cuadrado-Godia E, Campello AR, Roquer J, Moreira T, Mazya MV, Bandini F, Matz K, Iversen HK, González-Duarte A, Tiu C, Ferrari J, Vosko MR, Salzer HJF, Lamprecht B, Dünser MW, Cereda CW, Quintero ÁBC, Korompoki E, Soriano-Navarro E, Soto-Ramírez LE, Castañeda-Méndez PF, Bay-Sansores D, Arauz A, Cano-Nigenda V, Kristoffersen ES, Tiainen M, Strbian D, Putaala J, Lip GYH
doi: 10.1161/STROKEAHA.120.031208.